Literature DB >> 33467725

Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.

Yueyuan Zhou1,2, Yusuke Yamamoto2, Fumitaka Takeshita3, Tomofumi Yamamoto2, Zhongdang Xiao1, Takahiro Ochiya2,4.   

Abstract

Programmed cell death ligand-1 (PD-L1) overexpressed on cancer cells has emerged as a key inhibitor that maintains the immunosuppressive microenvironment through its interaction with the PD-1 receptor in cancer. Here, we demonstrated that miR-424-5p delivery via extracellular vesicles (EVs) derived from adipose tissue-mesenchymal stromal cells (AT-MSCs) partly promotes proinflammation and enhances antitumor cytotoxicity in vitro and in vivo. Triple negative breast cancer (TNBC) exhibits increased expression of PD-L1, and PD-L1 is positively correlated with the overall survival of patients with TNBC. PD-L1 shows relatively higher expression in MDA-MB-231 (MM231) cells and can be downregulated by miR-424-5p. Furthermore, miR-424-5p transported by EVs can increase the secretion of proinflammatory cytokines, decrease the secretion of anti-inflammatory cytokines and promote the apoptosis of tumor cells. The intratumoral administration of miR-424-5p-EVs significantly slowed tumor growth. In conclusion, these results demonstrate that EVs may serve as a delivery system for novel immunotherapies for TNBC through the miR-424-5p/PD-L1 pathway.

Entities:  

Keywords:  PD-L1; exosome; mesenchymal stromal cell; miR-424-5p; triple-negative breast cancer

Mesh:

Substances:

Year:  2021        PMID: 33467725      PMCID: PMC7831022          DOI: 10.3390/ijms22020844

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  53 in total

Review 1.  Exosomes: extracellular organelles important in intercellular communication.

Authors:  Suresh Mathivanan; Hong Ji; Richard J Simpson
Journal:  J Proteomics       Date:  2010-07-01       Impact factor: 4.044

2.  Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.

Authors:  Joanna Kowal; Guillaume Arras; Marina Colombo; Mabel Jouve; Jakob Paul Morath; Bjarke Primdal-Bengtson; Florent Dingli; Damarys Loew; Mercedes Tkach; Clotilde Théry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

Review 3.  Mesenchymal stem cells: Cell therapy and regeneration potential.

Authors:  Christina Brown; Christina McKee; Shreeya Bakshi; Keegan Walker; Eryk Hakman; Sophia Halassy; David Svinarich; Robert Dodds; Chhabi K Govind; G Rasul Chaudhry
Journal:  J Tissue Eng Regen Med       Date:  2019-07-25       Impact factor: 3.963

4.  Analysis of Cell Viability by the Lactate Dehydrogenase Assay.

Authors:  Priti Kumar; Arvindhan Nagarajan; Pradeep D Uchil
Journal:  Cold Spring Harb Protoc       Date:  2018-06-01

5.  Prospective dual role of mesenchymal stem cells in breast tumor microenvironment.

Authors:  Christiane Senst; Timo Nazari-Shafti; Stefan Kruger; Kirstin Höner Zu Bentrup; Charles L Dupin; Abigail E Chaffin; Sudesh K Srivastav; Philipp M Wörner; Asim B Abdel-Mageed; Eckhard U Alt; Reza Izadpanah
Journal:  Breast Cancer Res Treat       Date:  2012-11-10       Impact factor: 4.872

6.  Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment.

Authors:  Yan Zhang; Alexes C Daquinag; Felipe Amaya-Manzanares; Olga Sirin; Chieh Tseng; Mikhail G Kolonin
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

7.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Authors:  Sherene Loi; Nicolas Sirtaine; Fanny Piette; Roberto Salgado; Giuseppe Viale; Françoise Van Eenoo; Ghizlane Rouas; Prudence Francis; John P A Crown; Erika Hitre; Evandro de Azambuja; Emmanuel Quinaux; Angelo Di Leo; Stefan Michiels; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

8.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Peter Schmid; Hope S Rugo; Sylvia Adams; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Vidya Maiya; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  Lancet Oncol       Date:  2019-11-27       Impact factor: 41.316

9.  Systemically Infused Mesenchymal Stem Cells Show Different Homing Profiles in Healthy and Tumor Mouse Models.

Authors:  Chengying Xie; Zhangru Yang; Yuanzhen Suo; Qianqian Chen; Dan Wei; Xiaofu Weng; Zhengqin Gu; Xunbin Wei
Journal:  Stem Cells Transl Med       Date:  2017-02-16       Impact factor: 6.940

Review 10.  The Interleukin-10 Family of Cytokines and Their Role in the CNS.

Authors:  Amanda R Burmeister; Ian Marriott
Journal:  Front Cell Neurosci       Date:  2018-11-27       Impact factor: 5.505

View more
  15 in total

1.  A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.

Authors:  Mahdi Abdoli Shadbad; Sahar Safaei; Oronzo Brunetti; Afshin Derakhshani; Parisa Lotfinejad; Ahad Mokhtarzadeh; Nima Hemmat; Vito Racanelli; Antonio Giovanni Solimando; Antonella Argentiero; Nicola Silvestris; Behzad Baradaran
Journal:  Genes (Basel)       Date:  2021-08-04       Impact factor: 4.096

Review 2.  Exosomal microRNAs in hepatocellular carcinoma.

Authors:  Chenbin Liu; Han Wu; Yinqi Mao; Wei Chen; Shuying Chen
Journal:  Cancer Cell Int       Date:  2021-05-08       Impact factor: 5.722

3.  miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.

Authors:  Anna Maria Grimaldi; Marco Salvatore; Mariarosaria Incoronato
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

4.  Culture Condition of Bone Marrow Stromal Cells Affects Quantity and Quality of the Extracellular Vesicles.

Authors:  Amanda L Scheiber; Cierra A Clark; Takashi Kaito; Masahiro Iwamoto; Edwin M Horwitz; Yuka Imamura Kawasawa; Satoru Otsuru
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 6.208

Review 5.  Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins.

Authors:  Soudeh Ghafouri-Fard; Bashdar Mahmud Hussen; Mahdi Mohaqiq; Hamed Shoorei; Aria Baniahmad; Mohammad Taheri; Elena Jamali
Journal:  Front Oncol       Date:  2022-03-23       Impact factor: 6.244

Review 6.  Application of engineered extracellular vesicles for targeted tumor therapy.

Authors:  Fusheng Zhang; Jinshuai Guo; Zhenghou Zhang; Meiqi Duan; Guang Wang; Yiping Qian; Haiying Zhao; Zhi Yang; Xiaofeng Jiang
Journal:  J Biomed Sci       Date:  2022-02-21       Impact factor: 8.410

Review 7.  Sequence Requirements for miR-424-5p Regulating and Function in Cancers.

Authors:  Jiangying Xuan; Yingxia Liu; Xiaoping Zeng; Hongmei Wang
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

Review 8.  Lipid-Based Nanovesicular Drug Delivery Systems.

Authors:  Tania Limongi; Francesca Susa; Monica Marini; Marco Allione; Bruno Torre; Roberto Pisano; Enzo di Fabrizio
Journal:  Nanomaterials (Basel)       Date:  2021-12-14       Impact factor: 5.076

Review 9.  Applications of Extracellular Vesicles in Triple-Negative Breast Cancer.

Authors:  Frederic St-Denis-Bissonnette; Rachil Khoury; Karan Mediratta; Sara El-Sahli; Lisheng Wang; Jessie R Lavoie
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

Review 10.  Exosomes as Emerging Drug Delivery and Diagnostic Modality for Breast Cancer: Recent Advances in Isolation and Application.

Authors:  Dulla Naveen Kumar; Aiswarya Chaudhuri; Farrukh Aqil; Deepa Dehari; Radha Munagala; Sanjay Singh; Ramesh C Gupta; Ashish Kumar Agrawal
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.